Why Merck $10.8 billion for a company with no approved drugs

Prometheus’s PRA023 is a candidate for treating autoimmune conditions

Related Keywords

California , United States , Robert Davis , Elizabeth Warren , Pfizer , Reuters , Prometheus Bioscience , New Jersey Based , Merck , Health , Medical , Dharma , Clinical Medicine , Pra023 , Pharmaceutical Industry , Ulcerative Colitis , Breakthrough Therapy , Roivant , Seagen , Antineoplastic Drugs , Prometheus Biosciences , Harmacology , Pembrolizumab , Keytruda , Pharmacy , Medicine , Uartz ,